Results 21 to 30 of about 737 (141)

Real-World Evaluation Study of Azvudine for the Treatment of Patients With COVID-19: A Systematic Review and Meta-Analysis [PDF]

Canadian Journal of Infectious Diseases and Medical Microbiology
Conclusions: Azvudine significantly reduced the hospitalization time and the time to nucleic acid conversion to negative in COVID-19 patients and significantly lowered all-cause mortality (Grading of Recommendations Assessment, Development, and ...
Abiden Kapar, Huling Li, Qian He, Dandan Lin, Dandan Tang, Kai Peng, Yida Wang, Kai Wang   +7 more
doaj   +3 more sources

Real-world effectiveness and safety of oral Azvudine versus Paxlovid for COVID-19 in patients with kidney disease: a multicenter, retrospective, cohort study [PDF]

BMC Infectious Diseases
Background Patients with kidney disease (KD) are at high risk of contracting COVID-19 and developing severe disease. There is still a lack of guidance regarding the treatment of COVID-19 in patients with KD.
Benchen Rao, Daming Wang, Mengzhao Yang, Chunyu Zhao, Ming Cheng, Silin Li, Donghua Zhang, Hong Luo, Guowu Qian, Ling Wang, Shixi Zhang, Guotao Li, Guangming Li, Zujiang Yu, Zhigang Ren   +14 more
doaj   +3 more sources

Efficacy of Nirmatrelvir-Ritonavir versus Azvudine for COVID-19 Treatment in Tibet: A Retrospective Study [PDF]

Infection and Drug Resistance, 2023
Xiang Zhao,1 Yuan Cheng,1 Meng Zhang,1 Bianba Qianda,2 Baima Zhouma,3 Bianba Yangzhen,3 Yao Zheng,4 Shuo Zhang,5 Huiying Zhao6 1Department of Respiratory and Critical Care Medicine, Peking University First Hospital, Beijing, People’s Republic of China ...
Zhao X, Cheng Y, Zhang M, Qianda B, Zhouma B, Yangzhen B, Zheng Y, Zhang S, Zhao H   +8 more
doaj   +3 more sources

The effectiveness and safety of azvudine treatment in COVID‐19 patients with kidney disease based on a multicenter retrospective cohort study [PDF]

View
Kidney disease has been the main risk factor of poor prognosis for COVID‐19 patients. The effectiveness and safety of azvudine treatment in COVID‐19 patients with kidney disease have not been reported. Herein, we conducted a nine‐center and retrospective
Bo Yu, Mengzhao Yang, Jia Yu, Daming Wang, Hong Luo, Ming Cheng, Shixi Zhang, Guotao Li, Ling Wang, Guowu Qian, Donghua Zhang, Silin Li, Zhigang Ren, Quancheng Kan   +13 more
doaj   +3 more sources

Effectiveness of azvudine in reducing mortality of COVID-19 patients: a systematic review and meta-analysis [PDF]

Virology Journal
Background Azvudine has been approved for the treatment of coronavirus disease 2019 (COVID-19) patients in China, and this meta-analysis aims to illustrate the safety of azvudine and its effectiveness in reducing mortality. Methods PubMed, Embase, Web of
Yaqi Wang, Huaiya Xie, Luo Wang, Junping Fan, Ying Zhang, Siqi Pan, Wangji Zhou, Qiaoling Chen, Xueqi Liu, Aohua Wu, Hong Zhang, Jinglan Wang, Xinlun Tian   +12 more
doaj   +4 more sources

Comparison of azvudine, molnupiravir, and nirmatrelvir/ritonavir in adult patients with mild-to-moderate COVID-19: a retrospective cohort study [PDF]

Scientific Reports
This study aimed to explore the effectiveness and safety of azvudine, nirmatrelvir/ritonavir, and molnupiravir in adult patients with mild-to-moderate COVID-19.
Mei-Ping Chen, Di-Xuan Jiang, Jia-Xi Rang, Hai-Bo Zhuo, Zhi-Guo Zhou   +4 more
exaly   +3 more sources

Systematic evaluation of therapeutic effectiveness of Azvudine in treating COVID-19 hospitalized patients: a retrospective cohort study [PDF]

Frontiers in Cellular and Infection Microbiology
BackgroundAzvudine, a repurposed oral small molecule antiviral drug, has potential effects in combating the SARS-CoV-2 virus. However, studies on its clinical efficacy in patients with COVID-19 are still limited and controversial, and further research ...
Yingkai Xu, Yingkai Xu, Yuan Huang, Zihan Yuan, Zihan Yuan, Wanbing Liu, Li Wang, Lei Liu   +7 more
doaj   +5 more sources

Efficacy and safety evaluation of Azvudine in the prospective treatment of COVID-19 based on four phase III clinical trials [PDF]

Frontiers in Pharmacology, 2023
Azvudine (FNC) is a synthetic nucleoside analog used to treat adult patients living with human immunodeficiency virus-1 (HIV-1) infection with high viral load.
Ke-Wei Zhu
doaj   +3 more sources

Comparison of the therapeutic effect of Paxlovid and Azvudine in the treatment of COVID-19: A retrospective study [PDF]

Journal of Infection and Public Health
Background: COVID-19 pneumonia has spread across China and globally since late 2019, becoming a pandemic. Its extremely contagious nature as well as high morbidity and mortality rates have attracted widespread attention globally.
Wei Yang, Weiting Zhang, Jing Zhou, Xinyue Ma, Changsong Wang, Mingyan Zhao, Kaijiang Yu   +6 more
doaj   +4 more sources

Azvudine, a novel nucleoside reverse transcriptase inhibitor showed good drug combination features and better inhibition on drug-resistant strains than lamivudine in vitro. [PDF]

PLoS ONE, 2014
Azvudine is a novel nucleoside reverse transcriptase inhibitor with antiviral activity on human immunodeficiency virus, hepatitis B virus and hepatitis C virus. Here we reported the in vitro activity of azvudine against HIV-1 and HIV-2 when used alone or
Rui-Rui Wang, Qing-Hua Yang, Rong-Hua Luo, You-Mei Peng, Shao-Xing Dai, Xing-Jie Zhang, Huan Chen, Xue-Qing Cui, Ya-Juan Liu, Jing-Fei Huang, Jun-Biao Chang, Yong-Tang Zheng   +11 more
doaj   +2 more sources